Prab at 13:04, 18 March 2025

2025-03-18T13:04:40Z

← Older revision		Revision as of 13:04, 18 March 2025
Line 146:		Line 146:
	[[Category:Withdrawn drugs]]		[[Category:Withdrawn drugs]]
	{{No image}}		{{No image}}
	~~__NOINDEX__~~

Prab: CSV import

2025-03-17T20:44:19Z

CSV import

← Older revision		Revision as of 20:44, 17 March 2025
Line 146:		Line 146:
	[[Category:Withdrawn drugs]]		[[Category:Withdrawn drugs]]
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-11T04:34:47Z

CSV import

← Older revision		Revision as of 04:34, 11 February 2025
Line 145:		Line 145:
	[[Category:Eli Lilly and Company brands]]		[[Category:Eli Lilly and Company brands]]
	[[Category:Withdrawn drugs]]		[[Category:Withdrawn drugs]]
			{{No image}}

Deepika vegiraju at 14:24, 19 August 2021

2021-08-19T14:24:53Z

New page

== '''What is Olaratumab?''' ==

Olaratumab ('''LARTRUVO''') is a '''[[platelet]]-derived growth factor receptor alpha (PDGFR-α) blocking antibody''' used in the therapy of advanced [[soft tissue sarcoma]].

<youtube>
title='''{{PAGENAME}}'''
movie_url=http://www.youtube.com/v/v=8mBxprvxYWQ
embed_source_url=http://www.youtube.com/v/v=8mBxprvxYWQ
&rel=1
wrap = yes
width=750
height=600
</youtube>

== '''What are the uses of this medicine?''' ==

* This medicine is used in combination with [[doxorubicin]], for the treatment of adult patients with [[soft tissue sarcoma]] (STS) with a histologic subtype for which an [[anthracycline]]-containing regimen is appropriate and which is not amenable to curative treatment with [[radiotherapy]] or surgery.
* This indication is approved under accelerated approval.

== '''How does this medicine work?''' ==

* Olaratumab (oh" lar at' ue mab) is a '''recombinant human monoclonal IgG1 antibody to the platelet-derived growth factor receptor alpha'''.
* '''Signaling through PDGF receptors promotes cell proliferation and angiogenesis'''.
* '''Inhibition of the PDGF signaling decreases formation of new blood vessels''', which plays an important role in growth and spread of cancer cells.
* When used in combination with other [[antineoplastic agents]], olaratumab has been shown to extend recurrence-free survival in several forms of advanced cancer.

== '''Who Should Not Use this medicine ?''' ==

* This medicine have no usage limitations.

== '''What drug interactions can this medicine cause?''' ==

* No clinically important drug interactions have been observed with LARTRUVO.

== '''Is this medicine FDA approved?''' ==

* It was approved for use in the United States in 2016.

== '''How should this medicine be used?''' ==

* Premedicate with [[diphenhydramine]] and [[dexamethasone]] intravenously, prior to LARTRUVO on Day 1 of cycle 1.

'''Recommended Dosage:'''
* The recommended dose of LARTRUVO is 15 mg/kg administered as an intravenous infusion over 60 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.
* For the first 8 cycles, LARTRUVO is administered with [[doxorubicin]].

'''Administration'''
* Inspect vial contents for particulate matter and discoloration prior to dilution.
* Discard the vial if particulate matter or discolorations are identified.
* Withdraw calculated dose and further dilute with 0.9% Sodium Chloride Injection, USP to a final volume of 250 mL for intravenous infusion.
* Do not use dextrose-containing or other solutions.
* Gently invert but do not shake.
* DO NOT FREEZE the diluted solution.
* Store the diluted solution for up to 24 hours under refrigeration at 2°C to 8°C (36°F to 46°F) and for up to an additional 8 hours at room temperature (below 25°C [77°F]).
* Storage times include the duration of infusion.
* If refrigerated, allow the diluted solution to come to room temperature prior to administration.
* Discard vial with any unused portion of LARTRUVO.
* Do not administer LARTRUVO as an intravenous push or bolus.
* Do not co-infuse with electrolytes or other medications through the same intravenous line.
* Visually inspect the diluted solution for particulate matter and discoloration prior to administration.
* If particulate matter or discolorations are identified, discard the solution.
* Administer diluted solution as an intravenous infusion over 60 minutes.
* Flush the line with 0.9% Sodium Chloride Injection, USP at end of infusion.

== '''What are the dosage forms and brand names of this medicine?''' ==

This medicine is available in fallowing doasage form:
* '''As Injection:''' 500 mg/50 mL (10 mg/mL) or 190 mg/19 mL (10 mg/mL) clear to slightly opalescent, colorless to slightly yellow solution in a single-dose vial.

This medicine is available in fallowing brand namesː
*'''LARTRUVO'''

=='''What side effects can this medication cause?'''==

The most common side effects and laboratory abnormalities of this medicine include:
* nausea
* fatigue
* musculoskeletal pain
* [[mucositis]]
* [[alopecia]]
* vomiting
* [[diarrhea]]
* decreased appetite
* abdominal pain
* [[neuropathy]]
* headache
* [[lymphopenia]]
* [[neutropenia]]
* [[thrombocytopenia]]
* [[hyperglycemia]]
* elevated aPTT
* [[hypokalemia]]
* [[hypophosphatemia]]

==''' What special precautions should I follow?''' ==

* Infusion-related reactions (IRR) occurred in 70 (14%) of 485 patients who received at least one dose of LARTRUVO. Monitor for signs and symptoms during and following infusion. Discontinue LARTRUVO for Grade 3 or 4 infusion-related reactions.
* LARTRUVO Can cause fetal harm. Advise females of potential risk to the fetus and to use effective contraception during treatment with LARTRUVO and for 3 months after the last dose.

== '''What to do in case of emergency/overdose?''' ==

* {{overdose}}

== '''Can this medicine be used in pregnancy?''' ==

* There are no available data on LARTRUVO use in pregnant women.

=='''Can this medicine be used in children?'''==

* The safety and effectiveness of LARTRUVO in pediatric patients have not been established.

== '''What are the active and inactive ingredients in this medicine?''' ==

'''Active ingredient:'''
* olaratumab

'''Inactive ingredients:'''
* histidine
* histidine monohydrochloride
* glycine
* sodium chloride
* mannitol
* polysorbate 20
* water

== '''Who manufactures and distributes this medicine?''' ==

* '''Packager:''' Eli Lilly and Company.

== '''What should I know about storage and disposal of this medication?''' ==

* Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) until time of use.
* Keep the vial in the outer carton to protect from light.
* DO NOT FREEZE OR SHAKE the vial.

{{coststubd}}
{{Monoclonals for tumors}}
{{Growth factor receptor modulators}}
{{Portal bar | Medicine}}

[[Category:Monoclonal antibodies for tumors]]
[[Category:Orphan drugs]]
[[Category:Breakthrough therapy]]
[[Category:Eli Lilly and Company brands]]
[[Category:Withdrawn drugs]]

Olaratumab - Revision history

Prab at 13:04, 18 March 2025

Prab: CSV import

Prab: CSV import

Deepika vegiraju at 14:24, 19 August 2021